Phase II Study of Chemoradiotherapy with Toripalimab and Surufatinib for Limited-Stage Small Cell Lung Cancer

What this Trial Is About

Researchers are investigating whether combining surufatinib with immunotherapy and chemoradiotherapy can improve survival for patients with limited-stage small cell lung cancer LS-SCLC. This single-arm Phase II study explores the safety and effectiveness of adding surufatinib to the standard ADRIATIC regimen, which includes toripalimab and chemoradiotherapy, aiming to enhance treatment outcomes for LS-SCLC patients. Participants will receive four cycles of chemotherapy with etoposide combined with either cisplatin or carboplatin, alongside toripalimab and oral surufatinib taken on days 1 to 14 of each cycle. Radiotherapy to the chest begins no later than the third chemotherapy cycle. After completing chemoradiotherapy, patients who show complete response, partial response, or stable disease will continue with consolidation therapy using toripalimab and surufatinib. Prophylactic cranial irradiation is recommended before starting consolidation treatment. During the study, patients will undergo various assessments to monitor their response and safety, including tracking progression-free survival over two years as the primary outcome. Researchers will also evaluate overall survival, treatment-related side effects, and patient-reported outcomes up to one year after treatment. The total study period involves close monitoring and follow-up to assess both effectiveness and safety of the combined treatment approach.

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer